Portal de Periódicos da CAPES

What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?

2018; American Society of Clinical Oncology; Issue: 38 Linguagem: Inglês

10.1200/edbk_198805

1930-7020

Ramon Andrade De Mello, Luís Castelo-Branco, Pedro Castelo‐Branco, Daniel Humberto Pozza, Louis Vermeulen, Sofia Palacio, Matthew Salzberg, A. Craig Lockhart,

Esophageal Cancer Research and Treatment

Esophageal cancer and gastric cancer are aggressive diseases for which treatment approaches are facing a new era. Some molecular pathways, such as VEGF, EGFR, fibroblast growth factor receptor, PIK3CA, and PARP-1, have been studied, and novel targeted drugs are presumed to be developed in the near future. From The Cancer Genome Atlas report, 80% of Epstein-Barr virus tumors and 42% of tumors with microsatellite instability have PIK3CA mutations, suggesting that this pathway could be reevaluated as a possible target for new systemic treatment of gastric cancer. Notably, higher PARP-1 expression can be found in gastric cancer, which might be related to more advanced disease and worse prognosis. In addition, PD-L1 expression, high microsatellite instability, and mismatch repair deficiency can be found in gastric cancer, thus suggesting that immunotherapy may also play a role in those patients. We discuss trends related to the potential of novel therapies for patients with esophageal and gastric cancers in the near future.